Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Bassem Maximos MD MPH PA

Neither a doctor nor a teaching hospital

Research payments

$1,165,360

127 payments

Through program year 2025, Bassem Maximos MD MPH PA is reported as receiving $1,165,360 in research payments, across 127 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $175,578 14
2024 Research $109,502 17
2023 Research $89,261 15
2022 Research $401,514 44
2021 Research $316,388 36
2020 Research $73,118 1

Breakdown

Who paid Research payments · program years 2020–2025
  1. Janssen Research & Development, LLC $449,426 32 payments
  2. Evofem Biosciences, Inc. $283,262 30 payments
  3. Davol Inc. $124,044 3 payments
  4. Pfizer Inc. $107,940 32 payments
  5. Sumitomo Pharma America, Inc. $76,675 16 payments
  6. Sage Therapeutics, Inc. $73,118 1 payment
  7. Exeltis, USA Inc. $23,622 6 payments
  8. Sanofi US Services Inc. $20,884 3 payments
  9. Sanofi Pasteur Inc. $6,389 4 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Ad26.COV2.S in Healthy Pregnant Participants $449,426 32 payments
  2. Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection $164,084 18 payments
  3. Hem001 $124,044 3 payments
  4. Evaluation of EVO100 for Prevention of Urogenital Chlamydia Trachomatis and Neisseria Gonorrhoeae Infection (EVOGUARD) $119,178 12 payments
  5. A Phase 3 Randomized Doubleblinded Placebocontrolled Trial to Evaluate the Efficacy and Safety of A Respiratory Syncytial Virus RSV Prefusion F Subunit Vaccine in Infants Born to Women Vaccinated During Pregnancy $107,940 32 payments
  6. A Study to Evaluate the Efficacy and Safety of Sage-217 in Participants With Severe Postpartum Depression (PPD) $73,118 1 payment
  7. A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids Or Endometriosis $42,312 9 payments
  8. Phase III, Randomized, Observer-blind, Placebo-controlled, Multi-center, Multinational Study to Evaluate the Efficacy, Immunogenicity, and Safety of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL) $27,273 7 payments
  9. A Phase 3, Single-Arm, Open-Label Study to Evaluate the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are 18 to 50 Years of Age and at Risk for Pregnancy $25,788 2 payments
  10. Cf13303 $13,889 4 payments
What the money was spent on Research payments · program years 2020–2025
  1. Professional salary support $246,580 29 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record